Sandoz presented new medium-term targets and a long-term biosimilars growth strategy through 2030 and 2035 at an investor day in Basel on Tuesday.
The generic drugmaker confirmed its existing targets through 2028, which include a 24% to 26% margin. For 2030, the company aims for mid-to-high single-digit annual revenue growth at constant exchange rates and a core EBITDA margin of 25% to 27%.
